1. Background {#sec0005}
=============

The UK-based PIVOT trial examined whether patients with suppressed viral load (VL) on combination antiretroviral therapy could be safely switched to ritonavir-boosted protease inhibitor (PI) monotherapy, with regular HIV VL monitoring and prompt reintroduction of combination therapy for VL rebound (defined as a confirmed VL ≥50 copies/ml) \[[@bib0005]\]. The primary outcome in the trial was the loss of future drug options, defined as intermediate to high level resistance (predicted from genotype) to one or more licensed drugs in contemporary use. Resistance tests were performed at site laboratories using various Sanger sequencing assays.

Of the 296 patients who were allocated to PI monotherapy, 105 were genotyped at least once (153 resistance tests in total), and the primary outcome observed in six patients. Three of these six patients had reverse transcriptase mutations but no protease mutations. In two other patients, both of whom received darunavir monotherapy and had no prior PI exposure, L90M was the sole protease mutation detected; this is rarely selected de novo by darunavir and is a relatively common transmitted mutation \[[@bib0010], [@bib0015]\]. It appears therefore that only a single PI monotherapy patient (described below, patient A) experienced a loss of drug options due to a mutation (I50L) selected by study drug. However, a limitation of Sanger sequencing is its inability to detect viral variants below a threshold of approximately 20%.

1.1. Objectives {#sec0010}
---------------

To examine whether the main analysis of PIVOT had missed low frequency mutations, by applying a more sensitive sequencing methodology to selected stored samples.

1.2. Study design {#sec0015}
-----------------

We performed next generation sequencing (NGS) on all available frozen plasma samples with VL \>1000 copies/ml (irrespective of whether the formal definition of virological failure was fulfilled) that had been stored from patients who were randomised to PI monotherapy. NGS detects the same range of mutants than Sanger sequencing but with much higher sensitivity. Assays were performed at Public Health England, with sequencing performed using MiSeq Reagent Kit version 2 (Illumina) \[[@bib0020]\]. The threshold for low-frequency variant detection was set at 2%.

2. Results {#sec0020}
==========

Of 26 potential samples, 17 (all from different patients) were identified and successfully tested. One patient received atazavair, two patients lopinavir, and 14 patients darunavir, as ritonavir-boosted monotherapy. The median (IQR) HIV VL was 6780 (3333--10,729) copies/ml, the median (IQR) time since randomisation was 43 (33--53) weeks, and the median (IQR) interval between first detectable VL and the date of sample was 6 (4--8) weeks. 10 of the samples had previously been tested by Sanger sequencing from the same blood draw; a paired comparison showed 99.2% homology at the nucleotide level, using a NGS variant detection level of 20%. The 7 remaining samples were from patients who had been tested by Sanger sequencing at a different time point. Protease mutations were defined as major or accessory, and drug susceptibility predicted using the Stanford HIVdb algorithm (version 8.1.1) (<https://hivdb.stanford.edu/>).

NGS (median coverage depth 76,000, range 20,000--170,000) revealed minority variant mutations in three of the 17 patients tested, all of whom were infected with subtype C virus ([Table 1](#tbl0005){ref-type="table"}). Patient A, who received atazanavir as PI monotherapy, met the primary outcome due to an I50L mutation (patient 5 in Table 2 in main trial report \[[@bib0005]\]). NGS showed a previously undetected G73D mutation (frequency 10%), predicted to confer resistance to saquinavir (i.e. Stanford penalty score ≥10), at week 57. Notably, I50L was not detected as a minority variant at this time point despite its detection (as a mixture) by Sanger sequencing at week 48, and it was also absent by Sanger sequencing at week 71. This suggests that the mutation may have been stochastic rather than a result of drug selection pressure. The patient remained on atazanavir monotherapy throughout the period spanned by these three tests. The virus of patient B, who received darunavir monotherapy, expressed the I54T mutation (frequency 2%) at 48 weeks. Paradoxically, this mutation predicts resistance to all PIs other than darunavir, again calling into question whether it actually arose from drug selection pressure (further supported by the low level of this variant). The L89V mutation (frequency 5%), which predicts resistance to fosamprenavir, was detected at 41 weeks in patient C. This patient simplified treatment from lopinavir/tenofovir/emtricitabine to lopinavir monotherapy at trial entry. Given the inability to test patients at baseline, it is not possible to conclude whether the mutation emerged before or after trial entry.Table 1Resistance test results on the three patients with protease mutations additionally identified by NGS.Table 1SubjectDrugs received before PIVOTRegimen during PIVOT[a](#tblfn0005){ref-type="table-fn"}Weeks since randomisationViral load (copies/ml)Protease mutations by Sanger sequencing[b](#tblfn0010){ref-type="table-fn"}Protease mutations by NGS[b](#tblfn0010){ref-type="table-fn"}Predicted PI resistance[c](#tblfn0015){ref-type="table-fn"}ATDF, FTC, EFVATV/r4823,400I50I/L, K20K/TNDATV(H)573300K20K/TK20T (13%; 99,917), G73D (10%; 76,126)ATV(PL),FPV(PL),SQV(L)[d](#tblfn0020){ref-type="table-fn"}612400NoneNDBZDV, TDF, 3TC, FTC, EFVDRV/r4835,431NDI54T (2%; 112,532)ATV (L), LPV(L)5217,700NoneNDCTDF, FTC, LPV/rLPV/r4110,700NoneL89V (5%; 98,051)FPV(PL)[^2][^3][^4][^5][^6]

In summary, NGS did not identify any additional patients who met the trial primary outcome of intermediate or high level resistance. Furthermore, the phenotypic impact of low-level variants may be over-estimated by the Stanford algorithm, which was developed in the context of majority variants.

3. Discussion {#sec0025}
=============

This report adds to the body of evidence that ritonavir-boosted PI monotherapy rarely leads to the emergence of protease resistance mutations when used as a switch strategy with prompt detection of VL rebound and early re-introduction of effective combination therapy. The risk may be higher in a routine clinical study setting, where monitoring may be less intensive. However, studies of second-line PI monotherapy in settings without VL monitoring have found that protease resistances emerges slowly \[[@bib0025], [@bib0030]\] Another sensitive genotyping method, single genome sequencing (SGS), was used in two other trials of maintenance PI monotherapy. In the MONOI study, 9 patients who received darunavir PI monotherapy were tested; additional protease resistance mutations (at positions 32, 47, 50) were found on 1/50 viral clones from one patient \[[@bib0035]\]. In the OK04 study, SGS was performed on 11 patients who received lopinavir monotherapy; additional mutations were detected on 3/45 viral clones at positions 46 and 82 in two patients \[[@bib0040]\].

In spite of the substantial evidence of safety, PI monotherapy has failed to achieve wide clinical acceptance as a maintenance strategy in patients with established viral suppression, possibly due to a higher overall risk of virological rebound compared with combination therapy. However, recent analyses have shown that patients at lower risk of virological rebound can be readily identified \[[@bib0045]\] and that intensification of therapy achieves rapid re-suppression without development of resistance \[[@bib0005], [@bib0025]\]. It is also important to note that PI monotherapy precludes the development of resistance to NRTIs and NNRTIs. As drugs from these classes generally have a lower barrier to resistance, the overall burden of resistance in the long run may be less for PI monotherapy than for combination therapy. Finally, recent simplification trials have shown that dual therapy regimens consisting of a PI plus lamivudine are as effective as ongoing triple therapy in terms of short-term viral suppression \[[@bib0050], [@bib0055]\]. Our finding of minimal protease resistance with PI monotherapy should also generalise to these more potent regimens.
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[^1]: Members of the PIVOT Trial Team are listed in the supplementary Appendix of the main trial publication (reference 1).

[^2]: ND = not done.

[^3]: All three subjects remained on same regimens from randomisation to date of resistance test samples.

[^4]: Major or accessory mutations according to Stanford HIVdb Version 8.1.1. I50L is major mutation; all other listed mutations are accessory. Values in parentheses are frequency of mutation; depth of read at that position.

[^5]: Predicted by Stanford HIVdb Version 8.1.1, based on consensus NGS sequence (preferentially) or Sanger sequence. PL = potential low level, L = low level, H = high.

[^6]: Predicted to be susceptible to all drugs by mutations detected by Sanger sequencing.
